pneumonia and cardiac disease - thoracic
Post on 31-Oct-2021
3 Views
Preview:
TRANSCRIPT
Pneumoniaand Cardiac Disease
Is pneumonia the egg?
Grant WatererMBBS PhD MBA FRACP FCCP MRCP
Professor of Medicine, University of Western AustraliaProfessor of Medicine, Northwestern University, Chicago
Conflicts of interest
• Advisory boards + speaking for AstraZeneca, GlaxoSmithKline, Menarini– Relevant to any discussions around ICS + pneumonia
Am J Respir Crit Care Med 2015
Is it really pneumonia?308 Patients presenting to ED with Clinical Features of pneumonia
CXR
Clinician Diagnosis
188 Pneumonia - YES 120 Pneumonia - NO
CT CT
132 Pneumonia - YES56 Pneumonia - NO
40 Pneumonia - YES80 Pneumonia - NO
Acute outcomes in pneumonia
Mortensen et al Arch Intern Med 2002Mortensen et al Arch Intern Med 2004
Acute RTI’s increase risk of AMI in short term
Meier et al Lancet 1998
Acute RTI’s increase risk of AMI in short term
0
1
2
3
4
5
6
1‐3 Days 4‐7 Days 8‐14 Days 15‐28 Days 29‐91 Days
Smeeth et al N Engl J Med 2004
OR fo
r AMI
Increase risk of cardiac events in acute pneumococcal CAP
Musher et al Clin Infect Dis 2007
EVENT NUMBER of EVENTS
Myocardial infarction 7.1%
New arrhythmia 4.6%
New CHF 7.6%
Total patients with Cardiac Event 19.4%
170 consecutive patients with pneumococcal pneumonia
Increase risk of AMI in acute CAP
Ramirez et al Clin Infect Dis 2008
Risk of AMI or Stroke post AECOPD
0
0.5
1
1.5
2
2.5
1‐5 days 6‐10 days 11‐15 days 16‐49 days
IHDStokeRe
lative
Risk
Donaldson et al Chest 2010
N=28847
New cardiac events and especially AMI are common in pneumonia
Arrhythmias are also common
• Soto‐Gomez et al Am J Med 2013• CAP in 32,689 patients from US VA system• 12% had a new cardiac arrhythmia documented within in 90‐days of admission
• Mostly AF
Soto-Gomez et al Am J Med 2013
Is arrhythmia an effect of macrolides?
Mortensen et al JAMA 201473,690 patients from the VA database with pneumonia
Mortensen et al JAMA 2014
73,690 patients from the VA database with pneumonia
Pathogenesis?
Short term risk of AMI
• Inflammation induces a procoagulant state– More likely to thrombosis a critically narrowed vessel
• Inflammation destablizes atheromatousplaques– More likely to have acute plaque rupture
• Pneumonia increases heart rate and myocardial oxygen consumption– Decreased diastolic filling time– More vulnerable myocardium
Cangemi et al JACC 201431 AMI in 278 patients with CAP
Platelet activation predicts AMI in patients with pneumonia (SIXTUS trial)
Brown et al Am J Respir Crit Care Med 2015; PLoS Pathog 2014
Treatment/prevention options?
Aspirin?
• Oz et al Coron Art Dis 2013• 108 pts with pneumonia• Randomised controlled trial 300mg aspirin per day for 1 month
• 91 (aspirin) vs 94 (control)• Highly selective troponin + ECG• 1 AMI vs 10 AMI p=0.015
Estimated survival during hospitalization of the aspirin group, compared to the nonaspirin group, using Kaplan–Meier survival analysis.
Falcone M et al. J Am Heart Assoc 2015;4:e001595
© 2015 Falcone M et al.
Prospective Observational study of 1005 patients 60yo+
Other anti‐platelets?
• Gross et al J Thromb Thromblysis 2013– 400,000 patients from Kentucky Medicare Database– 15,000 on clopidogrel– 2,908 pneumonias– OR for mortality 0.63
• Storey et al Platelets 2014– 18,421 patients in PLATO ticagrelor vs clopidogrel– Pneumonia events equivalent– Pneumonia deaths 7 vs 23 p=0.003
Other medications?
Wu et al PLOSOne 2014
Drug Odds Ratio 95%CI
Beta‐blocker 1.01 0.91‐1.13
Statin 1.10 0.99‐1.20
ACE Inhibitor 1.02 0.93‐1.12
ARBs 1.013 0.82‐1.28
Risk of Cardiac Adverse event in 21,985 patients with pneumoniafrom the US VA database
Pneumonia and acute CVD events?
• Under recognised• Under treated• Aspirin probably mandatory unless clear C.I.• Dose of aspirin probably 300mg for at least a month
• Possible other anti‐platelet therapy may be more efficacious – await TCAP results
Long‐term cardiac outcomes
Current Paradigm
• Patient gets pneumonia
• We treat the patient
• The patient gets better
• Discharge the patient satisfied we did our job
Mortality due to CAPInpatient mortality
Mortality in the subsequent2 years
0 200 400 600 800 1000
Days post discharge
1.0
0.9
0.8
0.7
0.6
0.5
45-64 yr
65-75 yr
> 75 yr
18-44yr
Long term survival after pneumoniaBrancati et al Lancet 1993;342:30-33
Koivula et al 1999
112 patients with CAP
Finland4167 60yo+
Vergis et al Arch Int Med 2001110 cases110 Age + ADL matched controlsNursing home population
Kaplan et al Arch Intern Med 2003
• Medicare database of Americans aged 65+• 159,000 CAP and 794,000 hospitalised controls• One year mortality 33.6% vs 24.9% (p<0.001)• vs population controls standardised 1‐year mortality 2.69
• Excess mortality unexplained
Mortensen et al Clin Infect Dis 2003
5‐year survival vs population control statistics
One or more co‐morbiditiesNo co‐morbidities
Age Group
18-40 +
41-60 ■
61-80 ○
81+ ▲
Age Group
18-40 +
41-60 ■
61-80 ○
81+ ▲
Waterer et al Am J Respir Crit Care Med 2005
14%20%
0 200 400 600 800 1000 1200 1400 1600 0 200 400 600 800 1000 1200 1400 1600
Days post discharge
Survi
val (P
ropo
rtion)
0
0.1
0.2
0
.3
0.4
0
.5
0.6
0.7
0.
8 0
.9
1.0
3‐year Mortality vs Expected Mortality in patients with no comorbidites
Age Group
AbsoluteDifference
Relative Difference
18-40 years
1.1% 3.0
41-60 years
9.6% 6.6
61-80 years
8.0% 2.0
Cangemi et al Am J Cardiol 2015
Cangemi et al Am J Cardiol 2015
Pneumonia and subsequent IHD• Corales‐Medina et al JAMA 2015• 5888 pts in Cardiovascular heart Study
– Aged 65+– 1989‐1994
• 15792 in the Atherosclerosis risk in communities study– Aged 45‐64– 1987‐1989
• All pneumonias matched to 2 controls• 10‐year follow up• Risk of IHD adjusted for cardiac risk factors + comorbidities
Pneumonia and Stroke/AMI
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
6
0‐30 31‐90 91‐365
Time post discharge (days)
OR fo
r new
onse
t IHD
or st
roke
Corales-Medina et al JAMA 2015
CHS (n=5888)ARIC (n=15792)
Corrales-Medina et al JAMA 2015
Pneumonia and new onset heart failure
• Corales‐Medina et al Am Heart J 2015• 5613 pts in Cardiovascular heart Study• Aged 65+• 665 cases of pneumonia
Pneumonia and new onset heart failure
1
3
5
7
9
11
13
31‐90 91‐180 181‐365 1‐5 years
Time post discharge (days)
OR fo
r new
onse
t hea
rt fai
lure
Corales-Medina et al Am Heart J 2015
How do we mitigate the risk?• We don’t know
• Assess all cardiovascular risk factors at time of admission and follow up
• Aspirin unless contraindicated– Probably 300mg for first month
• Statin unless contraindicated?? How long??
• Exercise?
Can we tease out high risk patient groups?
Higher risk groups
• Older• Existing CVS risk factors• Pneumococcal disease• Bacteremia• ?
Yende et al Am J Respir Crit Care Med 2008
Recovery in Exercise Tolerance post CAP
0
10
20
30
40
50
60
70
80
90
100
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
19yo32yo64yo
Weeks after discharge
% of
6 mo
nth ac
tivity
Conclusion
• CVS events are much more common in both acute pneumonia and in the 1‐year after recovery than we have realised
• This needs immediate attention• You need to change your approach to pneumonia and especially post pneumonia care
• I give aspirin 300mg unless contraindicated• Research!!
top related